Stock Stories
Evaxion (EVAX) Stock Surging 39% Pre-market After Promising Clinical Data
Evaxion Biotech’s (Nasdaq: EVAX) shares surged 39.87% to $2.14 in premarket trading. Despite a minor dip of -0.65% to $1.53 in the previous session, the clinical-stage biotech firm focusing on AI-driven immunotherapies experienced a boost after sharing clinical data. Which Data Has EVAX Presented? Evaxion